Nivolumab and Ipilimumab Combination in Frontline mCRC

November 13, 2018
Michael J. Overman, MD

Michael J. Overman, MD, discusses recent data reported at the 2018 ESMO Congress for the frontline combination of nivolumab plus ipilimumab in microsatellite instability-high metastatic colorectal cancer.

Michael J. Overman, MD, professor of gastrointestinal and medical oncology at The University of Texas MD Anderson Cancer Center, discusses recent data reported at the 2018 ESMO Congress for the frontline combination of nivolumab (Opdivo) plus ipilimumab (Yervoy) in microsatellite instability-high metastatic colorectal cancer.

At 1 year, the progression-free survival was approximately 80% and the majority of patients had a response. This is dramatic activity to see in the frontline, Overman notes.